OncoCyte (NASDAQ:OCX) Now Covered by StockNews.com

StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX) in a report issued on Tuesday morning. The brokerage issued a sell rating on the stock.

A number of other equities research analysts have also recently weighed in on the company. Stephens reaffirmed an equal weight rating and set a $4.00 price target on shares of OncoCyte in a report on Wednesday, April 17th. Benchmark reissued a speculative buy rating and set a $5.00 target price on shares of OncoCyte in a report on Monday, April 15th. Finally, Needham & Company LLC boosted their target price on OncoCyte from $3.60 to $4.25 and gave the stock a buy rating in a report on Wednesday, April 24th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, OncoCyte currently has a consensus rating of Hold and a consensus target price of $4.06.

OncoCyte Stock Down 1.4 %

OCX opened at $2.49 on Tuesday. The business’s 50 day moving average is $2.87 and its 200-day moving average is $3.01. OncoCyte has a twelve month low of $2.08 and a twelve month high of $6.20.

Insider Buying and Selling

In related news, Director Andrew Arno purchased 33,898 shares of the company’s stock in a transaction on Thursday, April 11th. The shares were bought at an average price of $2.95 per share, with a total value of $99,999.10. Following the completion of the acquisition, the director now owns 69,054 shares of the company’s stock, valued at $203,709.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, major shareholder Broadwood Partners, L.P. purchased 2,420,000 shares of the company’s stock in a transaction on Thursday, April 11th. The shares were bought at an average price of $2.92 per share, with a total value of $7,066,400.00. Following the completion of the acquisition, the insider now owns 4,929,066 shares of the company’s stock, valued at $14,392,872.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Andrew Arno purchased 33,898 shares of the company’s stock in a transaction on Thursday, April 11th. The stock was bought at an average cost of $2.95 per share, for a total transaction of $99,999.10. Following the acquisition, the director now directly owns 69,054 shares of the company’s stock, valued at approximately $203,709.30. The disclosure for this purchase can be found here. Insiders have bought a total of 2,457,288 shares of company stock valued at $7,176,400 over the last quarter. Corporate insiders own 1.94% of the company’s stock.

OncoCyte Company Profile

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.